基于树突状细胞的淀粉样变性独特型疫苗接种-猫眼课题宝

基于树突状细胞的淀粉样变性独特型疫苗接种

批准号：

6265003

负责人：

MARTHA Q LACY

金额：

$2.01万

依托单位：

MAYO CLINIC ROCHESTER

依托单位国家：

美国

项目类别：

财政年份：

1998

资助国家：

美国

项目状态：

已结题

起止时间：

1998-12-01 至 1999-11-30

来源：

https://reporter.nih.gov/project-details/6265003

关键词：

amyloidosis blood /lymphatic neoplasm clinical research clinical trial phase I dendritic cells gene therapy human subject human therapy evaluation neoplasm /cancer therapy neoplasm /cancer vaccine transplantation

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

The specific aim of this study is to see if dendritic cell-based vaccination to idiotype will induce clinical remission in malignant plasma proliferative diseases. As of February 16, ten patients have been enrolled; four have completed the vaccinations. It is too soon to comment on results, however, we have not seen any patients develop progressive disease. None have yet gone off the study. At least one appears to be achieving a remission. We are planning to write a follow-up trial that will utilize low-dose immunomodulatory drugs as adjuvants to the dendritic cell-based vaccines. An RO-1 based on this work will be submitted to the National Cancer Institute by the June 1 deadline. So far, it is too early to have submitted any publications referable to this work, however, I am planning to submit an abstract to the International Multiple Myeloma workshop as well as to the American Society of Hematology meeting.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文